Home > Healthcare > Biotechnology > Biotechnology R&D > Proteinase K Market

Proteinase K Market Trends

Report ID: GMI11996
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Proteinase K Market Trends

Technological advancements in the market are driven by developments in biotechnology, enhancing the enzyme's applications across various sectors.

Advances in recombinant DNA technology have enabled the production of recombinant proteinase K, ensuring higher purity, stability, and consistent activity. This is particularly valuable for sensitive molecular biology applications, such as genomic DNA extraction and diagnostic testing.
Innovations in stabilizing proteinase K in both liquid and powder forms are improving its shelf life and compatibility with various reagents. These advancements make the enzyme more suitable for automated processes and high-throughput systems, driving demand from biotech and pharmaceutical companies.
Proteinase K is also being increasingly used in emerging gene-editing technologies like CRISPR, where it aids in removing proteins and other contaminants from nucleic acid samples, enhancing the efficiency of the gene editing process.
Additionally, biotechnology advancements have facilitated the integration of proteinase K in next-generation diagnostic platforms, including nucleic acid amplification testing and sequencing-based diagnostics. This is critical for applications in infectious disease detection and precision medicine. These advancements in biotechnology are broadening the scope of proteinase K, driving its adoption across diagnostics, research, and drug development sectors.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global proteinase K industry was valued at approximately USD 1.3 billion in 2023 and is estimated to grow at a 7.5% CAGR from 2024 to 2032, driven by the increasing prevalence of chronic and infectious diseases and advancements in biotechnology.

The powdered proteinase K segment dominated the market in 2023, accounting for USD 735.7 million, due to its greater stability, longer shelf life, and easier storage conditions compared to its liquid counterpart.

U.S. led the North American proteinase K market with revenues of USD 456.2 million in 2023, supported by numerous academic and research institutions engaged in genetic and cellular research and increased federal funding for scientific research.

Key players in the proteinase K industry include Abcam, Agilent Technologies, Bioline (Meridian Biosciences), BIORON, F. Hoffmann-La Roche, Merck, Minerva Biolabs, MP BIOMEDICALS, New England Biolabs, and Norgen Biotek.